Dragomir A, et al. – This population–based study sought to inspect contemporary metastatic castration–resistant prostate cancer (MCRPc) management patterns and therapy utilization trends in Quebec. Results suggested patient age as a strong determinant in the selection of MCRPC therapy. It affected the probability of the use of chemotherapy, bone–targeted therapy, or palliative radiation therapy (RT). As per observations, the introduction of new therapies—such as bone–targeted therapy, docetaxel, and abiraterone—affected treatment selection over time. However, chemotherapy was still used only in a small percentage of patients.